Tammie L.S. Benzinger, MD, Ph.D.

Recently FDA-approved anti-amyloid monoclonal antibody therapy can potentially slow disease progression

PET-MRI offers a comprehensive approach to the evaluation and management of patients with Alzheimer’s disease (AD) and dementia, providing valuable insights into disease pathology, progression and treatment response. Its multi-modal imaging capabilities can enhance diagnostic accuracy and facilitate personalized patient care.

The recent FDA approvals of anti-amyloid monoclonal antibody therapies demonstrates the importance of PET-MRI to diagnose AD since this technology can simultaneously provide the required brain MRI for baseline safety as well as the required biomarker for beta-amyloid pathology… Continue reading.

WASHINGTON, D.C.— The American Institute for Medical and Biological Engineering (AIMBE) has announced the induction of Tammie L.S. Benzinger, MD, Ph.D., Professor at Washington University School of Medicine in St. Louis to its College of Fellows.

Election to the AIMBE College of Fellows is among the highest professional distinctions accorded to medical and biological engineers, comprised of the top two percent of engineers in these fields. College membership honors those who have made outstanding contributions to “engineering and medicine research, practice, or education” and to “the pioneering of new and developing fields of technology, making major advancements in traditional fields of medical and biological engineering or developing/implementing innovative approaches to bioengineering education.”

Dr. Benzinger was nominated, reviewed, and elected by peers and members of the College of Fellows “for pioneering contributions to the translation of MR and PET imaging to advance the diagnosis and treatment Alzheimer disease and dementia…. Continue reading.